The V2 vasopressin receptor mutations and fluid homeostasis

Cardiovascular Research

Volumn 51, Issue 3, 2001, Pages 409-415

  Birnbaumer, Mariel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Hormones; Intra extracellular ions; Receptors; Vasoactive agents

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN; DNA; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; INDOMETACIN; THIAZIDE DIURETIC AGENT; VASOPRESSIN V2 RECEPTOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DEHYDRATION; DIET THERAPY; DRUG EFFICACY; GENE MUTATION; GENE SEQUENCE; HOMEOSTASIS; HUMAN; HYPERNATREMIA; INFANCY; INTELLECTUAL IMPAIRMENT; KIDNEY CONCENTRATING CAPACITY; MOLECULAR CLONING; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PHYSICAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

DIABETES INSIPIDUS, NEPHROGENIC; HUMANS; MUTATION; RECEPTORS, VASOPRESSIN; WATER-ELECTROLYTE BALANCE;

EID: 0035882203     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00337-6     Document Type: Review

References (47)

1. Vasopressin isoreceptors in mammals: Relation to cAMP-dependent and cAMP-independent transduction mechanisms
2. Molecular cloning and expression of a rat V1a arginine vasopressin receptor
3. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor
4. Molecular cloning of the receptor for human antidiuretic hormone
5. The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels
6. Regulation of pituitary vasopressin receptors during chronic stress: Relationship to corticotroph responsiveness
7. The similarity of effects of vasopressin, adenosine 3′,5′-monophosphate(cyclic AMP) and theophylline on the toad bladder
8. Role of cyclic AMP in the action of neurohypophyseal hormones on kidney
9. Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla
10. Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla
11. Requirement of human renal water channel aquaporin-2 for vasopres sin-dependent concentration of urine
12. Molecular physiology of urinary concentrating mechanism: Regulation of aquaporin water channels by vasopressin
13. Renal actions of vasopressin
14. Osmoreceptors in the central nervous system
15. UT-A2: A 55-kDa urea transporter in thin descending limb whose abundance is regulated by vasopressin
16. Biosynthesis of vasopressin
17. Cell-specific gene expression in oxytocin and vasopressin magnocellular neurones
18. Nephrogenic diabetes insipidus
19. Molecular characterization of nephrogenic diabetes insipidus
20. Gene transfer, expression, and molecular cloning of the human transferrin receptor gene
21. Gene transfer and molecular cloning of the human NGF receptor
22. In situ assay of hormone-stimulated adenylyl cyclase in 96-well microtitration plates: An aid to rapid identification of transformed cell clones
23. Development and characterization of a mouse cell line expressing the human V2 vasopressin receptor gene
24. Structure and chromosomal localization of the human antidiuretic hormone receptor gene
25. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine]vasopressin in patients with congenital nephrogenic diabetes insipidus
26. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus
27. Epinephrin and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism
28. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus
29. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis
30. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insi pidus
31. Vasopressin V2 receptor mutants causing X-linked nephrogenic diabetes insipidus: Analysis of expression, processing and function
32. A fully active non-glycosylated V2 vasopressin receptor
33. O-glycosylation of the V2 vasopressin receptor
34. An X-linked NDI mutation reveals a requirement for cell surface V2R expression
35. Nephrogenic diabetes insipidus: A V2 vasopressin receptor unable to stimulate adenylyl cyclase
36. s/adenylyl cyclase system
37. Differential expression of the β-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: A quantitative evaluation
38. Biochemical basis of partial phenotype in X-linked recessive diabetes insipidus
39. Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: Molecular basis of a mild clinical phenotype
40. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
41. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide
42. Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication
43. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy
44. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR121463A, a new potent and highly selective V2 receptor antagonist
45. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
46. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
47. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men